CD30 Targeted Therapies
1 drugsAbout CD30
CD30 (TNFRSF8) is a transmembrane receptor protein found on activated lymphocytes and malignant cells, particularly in lymphomas. It belongs to the tumor necrosis factor receptor superfamily. Its expression patterns make it a therapeutic target.
CD30 is a valuable drug target despite the lack of genetic evidence directly linking it to specific diseases. Its presence on malignant cells makes it a compelling focus for therapeutic intervention in CD30-expressing conditions.
CD30 is targeted by one FDA-approved drug, ADCETRIS (brentuximab vedotin), an antibody-drug conjugate (ADC). ADCETRIS, developed by SEATTLE GENETICS, is approved for 6 indications in the 'other' therapeutic area.
Top CD30 Drugs
SEATTLE GENETICS is the only company with an approved drug targeting CD30.
High market concentration indicates potential entry barriers but also significant unmet need.
CD30 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CD30, using adc modality.
Explore alternative modalities to differentiate from existing therapies and expand market reach.
CD30 Clinical Trials 154 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CD30. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 48 | 29 | 14 | 3 | 67% |
| Phase 2 | 86 | 40 | 13 | 33 | 75% |
| Phase 3 | 15 | 5 | 2 | 8 | 71% |
| Phase 4 | 5 | 3 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved CD30 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting CD30. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
CD30 Drug Approval Timeline (2011 - 2011)
ADCETRIS was first approved in 2011 and remains the only approved drug.
The lack of recent approvals suggests a saturated market or challenges in developing new CD30-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 70 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CD30. A trial counts if an approved drug acting on CD30 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.